Prezista label
Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 1 effect
Not studied
Drug 2
Drug 2 effect
Not studied (may increase rapamycin levels)
Clinical Effects
Increased risk of sirolimus adverse effects (supratherapeutic immunosuppression)
Management
If coadministering, consider initiating lower immunosuppressant dose. Therapeutic drug monitoring is recommended. Consult with specialist as necessary.
Import ID
1001
